SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

NASDAQ:SLNO • US8342033094

37.24 USD
-1.39 (-3.6%)
At close: Feb 13, 2026
37.19 USD
-0.05 (-0.13%)
Pre-Market: 2/17/2026, 9:10:34 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SLNO. SLNO was compared to 521 industry peers in the Biotechnology industry. While SLNO seems to be doing ok healthwise, there are quite some concerns on its profitability. SLNO is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • SLNO had negative earnings in the past year.
  • In the past year SLNO has reported a negative cash flow from operations.
  • In the past 5 years SLNO always reported negative net income.
  • In the past 5 years SLNO always reported negative operating cash flow.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -13.08%, SLNO belongs to the top of the industry, outperforming 82.15% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -15.85%, SLNO belongs to the top of the industry, outperforming 85.60% of the companies in the same industry.
Industry RankSector Rank
ROA -13.08%
ROE -15.85%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SLNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, SLNO has more shares outstanding
  • SLNO has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SLNO is higher compared to a year ago.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 10.99 indicates that SLNO is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 10.99, SLNO belongs to the top of the industry, outperforming 83.88% of the companies in the same industry.
  • A Debt/Equity ratio of 0.10 indicates that SLNO is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.10, SLNO is doing worse than 62.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 10.99
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • SLNO has a Current Ratio of 16.08. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SLNO (16.08) is better than 92.71% of its industry peers.
  • A Quick Ratio of 15.88 indicates that SLNO has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 15.88, SLNO belongs to the best of the industry, outperforming 92.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.08
Quick Ratio 15.88
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.58% over the past year.
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SLNO will show a very strong growth in Earnings Per Share. The EPS will grow by 54.01% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y106.03%
EPS Next 2Y73.44%
EPS Next 3Y54.01%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 200M 400M 600M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • SLNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • SLNO is valuated reasonably with a Price/Forward Earnings ratio of 8.67.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SLNO indicates a rather cheap valuation: SLNO is cheaper than 98.27% of the companies listed in the same industry.
  • SLNO is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 8.67
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as SLNO's earnings are expected to grow with 54.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.44%
EPS Next 3Y54.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SLNO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (2/13/2026, 8:00:02 PM)

Premarket: 37.19 -0.05 (-0.13%)

37.24

-1.39 (-3.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-25
Inst Owners124.99%
Inst Owner Change-2.12%
Ins Owners1.26%
Ins Owner Change4.96%
Market Cap2.00B
Revenue(TTM)98.67M
Net Income(TTM)-78.45M
Analysts86.32
Price Target114.16 (206.55%)
Short Float %19.84%
Short Ratio6.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)419.9%
Min EPS beat(2)80.77%
Max EPS beat(2)759.03%
EPS beat(4)2
Avg EPS beat(4)207.86%
Min EPS beat(4)-7.96%
Max EPS beat(4)759.03%
EPS beat(8)3
Avg EPS beat(8)72.02%
EPS beat(12)5
Avg EPS beat(12)44.04%
EPS beat(16)8
Avg EPS beat(16)37.6%
Revenue beat(2)2
Avg Revenue beat(2)30.96%
Min Revenue beat(2)27.34%
Max Revenue beat(2)34.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.42%
PT rev (3m)-5.95%
EPS NQ rev (1m)13.68%
EPS NQ rev (3m)62.13%
EPS NY rev (1m)477.98%
EPS NY rev (3m)133.68%
Revenue NQ rev (1m)6.57%
Revenue NQ rev (3m)18.33%
Revenue NY rev (1m)2.99%
Revenue NY rev (3m)29.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.67
P/S 20.27
P/FCF N/A
P/OCF N/A
P/B 4.04
P/tB 4.09
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)4.29
Fwd EY11.53%
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS1.84
BVpS9.21
TBVpS9.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.08%
ROE -15.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.14%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.08
Quick Ratio 15.88
Altman-Z 10.99
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
EPS Next Y106.03%
EPS Next 2Y73.44%
EPS Next 3Y54.01%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.97%
EBIT Next 3Y70.33%
EBIT Next 5YN/A
FCF growth 1Y-9.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.95%
OCF growth 3YN/A
OCF growth 5YN/A

SOLENO THERAPEUTICS INC / SLNO FAQ

What is the ChartMill fundamental rating of SOLENO THERAPEUTICS INC (SLNO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLNO.


Can you provide the valuation status for SOLENO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SOLENO THERAPEUTICS INC (SLNO). This can be considered as Fairly Valued.


How profitable is SOLENO THERAPEUTICS INC (SLNO) stock?

SOLENO THERAPEUTICS INC (SLNO) has a profitability rating of 2 / 10.


Can you provide the financial health for SLNO stock?

The financial health rating of SOLENO THERAPEUTICS INC (SLNO) is 5 / 10.